High-risk older adult RSV vaccine program
• The RSV vaccines available for the 2024-25 season are Arexvy (GSK) and Abrysvo (Pfizer).
• The publicly funded High-Risk Older Adult program includes individuals who are aged 60 years and older and are also:
o residents of long-term care homes, Elder Care Lodges, or retirement homes
o patients in hospital receiving alternate level of care (ALC) including similar settings (for example, complex continuing care, hospital transitional programs)
o patients receiving hemodialysis or peritoneal dialysis
o recipients of solid organ or hematopoietic stem cell transplants
o individuals experiencing homelessness o individuals who identify as First Nations, Inuit, or Métis
• Eligible older adults will be able to receive a single publicly funded dose of either Arexvy or Abrysvo if they have not previously received a dose
• Re-immunization is not required for individuals who were vaccinated last year; studies indicate that the RSV vaccine offers multi-year protection.
• Individuals 60 years of age and older who do not qualify for a publicly funded dose of the RSV vaccine can purchase the vaccine with a prescription through their local pharmacy.
Publicly Funded RSV vaccine is not available in pharmacy.
Comments